Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype

Lara C. Pullen, PhD  |  February 1, 2016

“Our study provides possible mechanisms by which Met and 2DG reversed immuno-phenotypes in vivo. Met regulates cellular metabolism through complex mechanisms, including the inhibition of the mitochondrial respiratory chain complex I. Here, the Met + 2DG treatment decreased T cell mitochondrial oxygen consumption, as well as mTORC1 [mammalian target of rapamycin complex 1] signaling in both the TC and NZB/W models,” write the authors in their discussion.

They concluded their paper by suggesting that new therapies that target T cell metabolism may be useful for the treatment of SLE.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Yin Y, Choi SC, Xu Z, et al. Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med. 2015 Feb 11;7(274):274ra18. doi: 10.1126/scitranslmed.aaa0835

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:CD4metabolismT cell

Related Articles

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    A&R Abstracts – T CELLS

    August 1, 2011

    For Further Reading

    2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases

    February 16, 2016

    SAN FRANCISCO—Metabolomics could one day be a treasure map of information about inflammation in rheumatic disease. There are many metabolic pathways to pursue for clues on how to reverse this damaging process. “All of these signaling pathways are interrelated and affect each other,” said Douglas J. Veale, MD, director of translational research at Dublin Academic…

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences